Arrowhead Pharmaceuticals Reports $829.4 Million Revenue Growth and FDA Approval of REDEMPLO

Arrowhead Pharmaceuticals, Inc. reported significant financial growth in its fiscal year ending September 30, 2025, with total revenue reaching $829.4 million, a substantial increase from $3.6 million in the previous year. This surge in revenue was primarily driven by milestone payments from collaboration agreements with Sarepta Therapeutics, Sanofi, and GSK, including a notable $696.8 million from Sarepta related to the ARO-DM1 program. The company also achieved an operating income of $98.3 million, a stark contrast to the operating loss of $601.1 million reported in 2024. Despite this positive trend, Arrowhead recorded a net loss of $1.6 million, down from a net loss of $599.5 million the previous year, reflecting the ongoing costs associated with research and development.

In terms of operational developments, Arrowhead achieved a major milestone with the FDA's approval of its first commercial product, REDEMPLO (plozasiran), for the treatment of Familial Chylomicronemia Syndrome (FCS) in November 2025. The company has also made significant strides in its clinical pipeline, with 18 drug candidates currently in various stages of clinical trials, including ongoing Phase 3 studies for severe hypertriglyceridemia. The company has expanded its commercial capabilities to support the marketing of REDEMPLO and plans to build on this foundation for future product launches.

Arrowhead's workforce has grown to 711 full-time employees, reflecting its commitment to expanding its research and development capabilities and preparing for commercialization. The company has also invested in new facilities, including a state-of-the-art GMP manufacturing facility in Verona, Wisconsin, which is expected to enhance its production capacity for clinical and commercial needs. The company’s strategic partnerships with major pharmaceutical firms, such as Novartis and Takeda, further bolster its operational capacity and financial resources, providing additional funding and expertise for its product development efforts.

Looking ahead, Arrowhead anticipates continued growth driven by its expanding pipeline and successful commercialization of REDEMPLO. The company is focused on advancing its clinical candidates and exploring new therapeutic areas, while also navigating the complexities of regulatory approvals and market acceptance. Arrowhead's management remains optimistic about its future prospects, emphasizing the potential for its RNA interference (RNAi) technology to address previously untreatable diseases and improve patient outcomes. However, the company acknowledges the inherent risks and uncertainties associated with drug development, including regulatory challenges and market competition, which could impact its financial performance and operational plans.